Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer

Background: Ovarian cancer (OC) is the second most common gynecological malignancy and has a high mortality rate. The current chemotherapeutic drugs have the disadvantages of drug resistance and side effects. Myricetin, a kind of natural compound, has the advantages of easy extraction, low price, an...

Full description

Bibliographic Details
Main Authors: Hui-Wen Yang, Yan Lan, An Li, Han Wu, Zi-Wei Song, Ai-Ling Wan, Yue Wang, Shi-Bao Li, Shuai Ji, Zhong-Cheng Wang, Xin-Yu Wu, Ting Lan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Pharmacology
Subjects:
myricetin
epithelial-to-mesenchymal transition
TGF-β
ovarian cancer
PI3K/AKT
TGF-β/Smad
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1288883/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1288883/full

Similar Items